Whoop

Explainers

Plain-language answers to the questions people ask about Whoop, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

• What is the FDA Warning Letter to Whoop about Blood Pressure Insights?

  On July 14, 2025, the FDA issued a Warning Letter to Whoop finding that the company's marketing of Blood Pressure Insights (BPI), launched May 2025 for Whoop MG, positioned the feature beyond the general-wellness scope that does not require 510(k) clearance for diagnostic claims. Whoop refused to remove the feature, defended BPI as wellness, and faced a subsequent class action lawsuit; as of May 2026 the matter remains unresolved. Whoop's market-first posture vs Oura's December 2025 BP study before marketing is the biometric cohort's sharpest verified-vs-claimed exemplar pair.

• What is Whoop?

  Whoop is a subscription-only fitness + recovery biometric band, positioned within the biometric cluster as the subscription-only band cohort exemplar. $239 hardware + $239/yr subscription = ~$478 Year 1 effective cost (subscription-only model; hardware-cost subsidized). $10.1B Series G March 2026 lead Collaborative Fund (CORRECTED from earlier aggregator-quoted QIA/Mubadala framing per Agent A re-verify). BP Insights 'not for hypertension diagnosis' manufacturer framing vs FDA July 14, 2025 Warning Letter; class action late 2025/early 2026; dispute still UNRESOLVED as of May 2026 per Agent A re-verify. Editorial throughline: subscription-only band cohort exemplar + manufacturer-position-vs-FDA-position editorial framing (same framing as existing Whoop BP Warning Letter feature explainer, but applied at full-entity scope; full entity anchor surfaces commercial model + product features + funding state + FDA dispute as integrated context).

Current leadership (8)

• Will Ahmed Founder & CEOsecondary-verified
• Emily Capodilupo SVP Data Science & Researchsecondary-verified
• Kristen Holmes Principal Scientist / Global Head of Human Performancesecondary-verified
• Aurelian Nicolae Co-founder & Chief Hardware Engineersecondary-verified
• Jaime Waydo Chief Technology Officersecondary-verified
• Mich Chandlee Chief Financial Officersecondary-verified
• Garrett Bastable Chief Operating Officersecondary-verified
• Aurelian Broussard foundersince 2012-01-01secondary-verified

Founders (3)

• Will Ahmedcofounderfounded 2012-01-01
• John Capodilupocofounderfounded 2012-01-01no longer at company
• Aurelian Nicolaecofounderfounded 2012-01-01

Former / Previously (1)

• John Capodilupo Co-founder & former CTOsecondary-verified

Safety record

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Incidents affecting Whoop (3)

• Class action (Rowe v. WHOOP) alleges WHOOP falsely advertised BPI as medical-grade2025-11-18 · Other
• Class action (Lomeli v. WHOOP) alleges health-data sharing without consent2025-08-13 · Other
• FDA warning letter to Whoop: Blood Pressure Insights marketed beyond clearance2025-07-14 · Regulatory action

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Operated deployments (1)

• Whoop (5.0 / MG)Global

Operator customers (1)

• Whoop1 deployment

Peer companies

• Samsung Electronics4 models
• Butterfly Network2 models
• Abbott1 model
• Apple1 model
• Circular1 model
• Dexcom1 model

Financial state

Reporting basis

private_reported

Lifecycle stage

growth

Counterparty risk class

low

Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.

Funding rounds (7)

• Series G2026-03-31

  $575M(reported) · $10.1B post

  Investors: Collaborative Fund (lead), Qatar Investment Authority, Mubadala Investment Company, Abbott (strategic) (strategic), Mayo Clinic (strategic)

• Series F2023-01-01

  $120M(reported)

• Series E2021-01-01

  $200M(reported)

  Investors: SoftBank Vision Fund, Tiger Global Management, Spark Capital

• Series D2020-01-01

  $100M(reported)

• Series C2019-01-01

  $55M(reported)

• Series B2018-01-01

  $25M(reported)

• Series A2015-01-01

  $12M(reported)

Regulatory filings (1)

• fda_warning_letterfda warning letter · us_fdaactive2025-07-14

  Linked models: Whoop (5.0 / MG)

Sources (4)

1. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/whoop-inc-709755-07142025 ↗
2. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K243236 ↗
3. https://www.statnews.com/2026/05/21/whoop-fda-blood-pressure-dispute-unresolved/ ↗
4. https://techcrunch.com/2026/03/31/whoop-raises-575m-series-g-10-billion-valuation/ ↗

Common questions

What is Whoop?

Biometric-wearable company (Boston; founded 2012; Will Ahmed) of the subscription-only Whoop band (Strain/Recovery/Sleep + MG with ECG); $10.1B valuation. FDA cleared its ECG but warned it over uncleared blood-pressure marketing.

What does Whoop make?

Whoop has 1 robot model on the DEPLOY registry: Whoop (5.0 / MG) (Whoop builds both physical robots and the AI that runs them).

Is Whoop publicly traded?

No. Whoop is privately held and not publicly traded, per the DEPLOY registry.

Who competes with Whoop?

On the DEPLOY registry, peer companies to Whoop building in the same form factors include Samsung Electronics, Butterfly Network, Abbott, Apple.

Where is Whoop headquartered?

Whoop is headquartered in Boston, Massachusetts, USA.